An independent two-stage DCF analysis by a frontier AI model.
Johnson & Johnson represents the ultimate defensive stock. As one of only two U.S. corporations retaining an elite AAA credit rating, it is often viewed as being as financially secure as the U.S. government. Following the spin-off of its consumer health division (Kenvue), JNJ is now a highly focused, higher-margin entity concentrating exclusively on Innovative Medicine and MedTech.
This valuation model doesn't assume hyper-growth; rather, it prices in the immense value of certainty. In an increasingly volatile macro environment, JNJ's ability to consistently generate nearly $20B in Free Cash Flow annually commands a premium multiple by way of a heavily discounted WACC.
5.5% reflects realistic, single-digit expansion for a mature titan. The company's pipeline and strategic acquisitions in cardiovascular tech (like Shockwave Medical) provide steady upside, perfectly offsetting the inevitable patent cliffs of blockbuster drugs like Stelara. The scale of JNJ prevents explosive percentage growth.
<div class="assumption-grid" data-astro-cid-w32zjhjs> <div class="assumption-card" data-astro-cid-w32zjhjs> <div class="card-title" data-astro-cid-w32zjhjs>FCF Growth Rate (Y1-Y5)
2.5% is an alignment with global healthcare spending and long-term inflation. JNJ is fundamentally tied to the aging demographics of the developed world. It will continue to grow at or slightly above global GDP in perpetuity.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 1.5% | $297.73 | $223.30 | $178.64 | $148.87 | $127.60 |
| 2.0% | $357.28 | $255.20 | $198.49 | $162.40 | $137.42 |
| 2.5% | $446.60 | $297.73 | $223.30 | $178.64 | $148.87 |
| 3.0% | $595.47 | $357.28 | $255.20 | $198.49 | $162.40 |
| 3.5% | $893.20 | $446.60 | $297.73 | $223.30 | $178.64 |
■ Undervalued vs current price ■ Overvalued vs current price
Gemini models a conservative 5.5% growth rate to reflect JNJ's massive scale and maturity as an established healthcare provider. While the MedTech and Innovative Medicine divisions post-Kenvue spin-off are highly profitable, they are difficult to grow at double-digit rates without aggressive M&A.
A 6.5% discount rate was used. JNJ's AAA credit rating, deep economic moat, and 0.55 beta make it one of the least volatile investments in the market, allowing for a WACC very close to the risk-free rate.
JNJ carries significant long-term debt to finance operations and large acquisitions (like Abiomed and Shockwave Medical). With around $47.9B in debt against roughly $20B in cash, the net cash is -$27.8B, which reduces the final equity value.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.